S100A4, S100A8, and S100A9 had a similar pattern of expression and showed a higher level of immunopositive cells in the MNCs of healthy controls than in CLL patients, and demonstrated a higher level of expression in CD19+ cells than in MNCs of CLL patients (Figure 1). This evidence concerns the gene S100A4 and B-cell chronic lymphocytic leukemia.